-
Something wrong with this record ?
Mutation-based detection and monitoring of cell-free tumor DNA in peripheral blood of cancer patients
L. Benesova, B. Belsanova, S. Suchanek, M. Kopeckova, P. Minarikova, L. Lipska, M. Levy, V. Visokai, M. Zavoral, M. Minarik,
Language English Country United States
Document type Journal Article, Research Support, Non-U.S. Gov't, Review
- MeSH
- Apoptosis * MeSH
- DNA, Neoplasm blood genetics MeSH
- Humans MeSH
- Mutation * MeSH
- DNA Mutational Analysis instrumentation methods MeSH
- Neoplasms blood genetics pathology MeSH
- Necrosis MeSH
- Animals MeSH
- Check Tag
- Humans MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Review MeSH
Prognosis of solid cancers is generally more favorable if the disease is treated early and efficiently. A key to long cancer survival is in radical surgical therapy directed at the primary tumor followed by early detection of possible progression, with swift application of subsequent therapeutic intervention reducing the risk of disease generalization. The conventional follow-up care is based on regular observation of tumor markers in combination with computed tomography/endoscopic ultrasound/magnetic resonance/positron emission tomography imaging to monitor potential tumor progression. A recent development in methodologies allowing screening for a presence of cell-free DNA (cfDNA) brings a new viable tool in early detection and management of major cancers. It is believed that cfDNA is released from tumors primarily due to necrotization, whereas the origin of nontumorous cfDNA is mostly apoptotic. The process of cfDNA detection starts with proper collection and treatment of blood and isolation and storage of blood plasma. The next important steps include cfDNA extraction from plasma and its detection and/or quantification. To distinguish tumor cfDNA from nontumorous cfDNA, specific somatic DNA mutations, previously localized in the primary tumor tissue, are identified in the extracted cfDNA. Apart from conventional mutation detection approaches, several dedicated techniques have been presented to detect low levels of cfDNA in an excess of nontumorous (nonmutated) DNA, including real-time polymerase chain reaction (PCR), "BEAMing" (beads, emulsion, amplification, and magnetics), and denaturing capillary electrophoresis. Techniques to facilitate the mutant detection, such as mutant-enriched PCR and COLD-PCR (coamplification at lower denaturation temperature PCR), are also applicable. Finally, a number of newly developed miniaturized approaches, such as single-molecule sequencing, are promising for the future.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc13024398
- 003
- CZ-PrNML
- 005
- 20170615144740.0
- 007
- ta
- 008
- 130703s2013 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.ab.2012.06.018 $2 doi
- 035 __
- $a (PubMed)22750103
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Benesova, L $u Laboratory of Molecular Genetics and Oncology, Genomac Research Institute, 155 41 Prague, Czech Republic.
- 245 10
- $a Mutation-based detection and monitoring of cell-free tumor DNA in peripheral blood of cancer patients / $c L. Benesova, B. Belsanova, S. Suchanek, M. Kopeckova, P. Minarikova, L. Lipska, M. Levy, V. Visokai, M. Zavoral, M. Minarik,
- 520 9_
- $a Prognosis of solid cancers is generally more favorable if the disease is treated early and efficiently. A key to long cancer survival is in radical surgical therapy directed at the primary tumor followed by early detection of possible progression, with swift application of subsequent therapeutic intervention reducing the risk of disease generalization. The conventional follow-up care is based on regular observation of tumor markers in combination with computed tomography/endoscopic ultrasound/magnetic resonance/positron emission tomography imaging to monitor potential tumor progression. A recent development in methodologies allowing screening for a presence of cell-free DNA (cfDNA) brings a new viable tool in early detection and management of major cancers. It is believed that cfDNA is released from tumors primarily due to necrotization, whereas the origin of nontumorous cfDNA is mostly apoptotic. The process of cfDNA detection starts with proper collection and treatment of blood and isolation and storage of blood plasma. The next important steps include cfDNA extraction from plasma and its detection and/or quantification. To distinguish tumor cfDNA from nontumorous cfDNA, specific somatic DNA mutations, previously localized in the primary tumor tissue, are identified in the extracted cfDNA. Apart from conventional mutation detection approaches, several dedicated techniques have been presented to detect low levels of cfDNA in an excess of nontumorous (nonmutated) DNA, including real-time polymerase chain reaction (PCR), "BEAMing" (beads, emulsion, amplification, and magnetics), and denaturing capillary electrophoresis. Techniques to facilitate the mutant detection, such as mutant-enriched PCR and COLD-PCR (coamplification at lower denaturation temperature PCR), are also applicable. Finally, a number of newly developed miniaturized approaches, such as single-molecule sequencing, are promising for the future.
- 650 _2
- $a zvířata $7 D000818
- 650 12
- $a apoptóza $7 D017209
- 650 _2
- $a mutační analýza DNA $x přístrojové vybavení $x metody $7 D004252
- 650 _2
- $a DNA nádorová $x krev $x genetika $7 D004273
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a mutace $7 D009154
- 650 _2
- $a nekróza $7 D009336
- 650 _2
- $a nádory $x krev $x genetika $x patologie $7 D009369
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Belsanova, B $u -
- 700 1_
- $a Suchánek, Štěpán $7 xx0105313
- 700 1_
- $a Kopeckova, M $u -
- 700 1_
- $a Minarikova, P $u -
- 700 1_
- $a Lipska, L $u -
- 700 1_
- $a Levy, M $u -
- 700 1_
- $a Visokai, V $u -
- 700 1_
- $a Zavoral, Miroslav, $d 1953- $7 xx0036686
- 700 1_
- $a Minarik, M $u -
- 773 0_
- $w MED00000335 $t Analytical biochemistry $x 1096-0309 $g Roč. 433, č. 2 (2013), s. 227-34
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/22750103 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20130703 $b ABA008
- 991 __
- $a 20170615145155 $b ABA008
- 999 __
- $a ok $b bmc $g 988078 $s 822778
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2013 $b 433 $c 2 $d 227-34 $i 1096-0309 $m Analytical biochemistry $n Anal Biochem $x MED00000335
- LZP __
- $a Pubmed-20130703